Mirum Q1 net sales $159.9M, raises FY guidance to $660-680M; volixibat & brelovitug meet primary endpoints

Mirum Pharmaceuticals, Inc.

2026-Q1 EPS reported -$13.43 revenue$159,882,000

Q1 2026 net product sales $159.9M, up 43% YoY; LIVMARLI $113.8M (+55%), Bile Acid Medicines $46.1M (+20%).
Full-year 2026 net product sales guidance raised to $660-680M from prior range.
Volixibat VISTAS Phase 2b in PSC met primary endpoint; NDA submission expected H2 2026.
Brelovitug AZURE-1 Phase 2b in HDV met primary endpoint; Phase 3 enrollment complete, topline H2 2026.
In-licensed zilurgisertib for FOP from Incyte for $16M upfront; FDA Priority Review, PDUFA Sept 26, 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Mirum Pharmaceuticals, Inc. reported the quarter ended March 31, 2026 results: revenue $159.9 million. Guidance raised.

Period: the quarter ended March 31, 2026
Revenue: $159.9 million
Guidance: raised
Result: reported results

Exact text from the filing

in such filing. --- EX-99.1 (EX-99.1) --- Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update – Q1 2026 net product sales of $159.9 million – 2026 net product sales guidance increased to $660 to $680 million – Volixibat VISTAS Phase 2b study met primary endpoint – Brelovitug Phase 2b portion of AZURE-1 study met

View on SEC.gov

Browse all earnings releases →

Mirum Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001759425-26-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.